Amanta Reports Q2 Revenue of ₹83.1 Crore Versus ₹70.9 Crore YoY

Market snapshot: Amanta Healthcare reported Q2 revenue of ₹83.1 crore, reflecting an increase from ₹70.9 crore in the corresponding period last year. The performance underscores steady top-line growth across its core pharmaceutical manufacturing business.

Data Snapshot

• Q2 revenue reached ₹83.1 crore compared to ₹70.9 crore in the same period last financial year.
• Year-over-year revenue growth recorded at ≈17.21% (derived: ₹83.1 cr vs ₹70.9 cr).

What's Changed

• Quarterly revenue expanded to ₹83.1 crore from ₹70.9 crore YoY.
• Top-line growth momentum accelerated by ≈17.21% YoY.

Key Takeaways

• Top-line Expansion: Q2 revenue increased to ₹83.1 crore from ₹70.9 crore in the prior-year quarter.
• Growth Pace: Revenue registered a YoY growth rate of ≈17.21%.
• Operational Continuity: Solid financial delivery driven by core pharmaceutical operations.

SAHI Perspective

Amanta Healthcare's top-line increase to ₹83.1 crore highlights consistent volume off-take in its sterile liquid manufacturing segments. The YoY growth rate of ≈17.21% reflects steady execution in meeting market demand.

Market Implications

The positive top-line growth provides baseline fundamental support for investor sentiment around the stock. Continued execution on production efficiency and cost optimization will remain key to converting revenue gains into sustainable operating profits.

Trading Signals

Market Bias: Bullish

Q2 revenue expansion to ₹83.1 crore from ₹70.9 crore (≈17.21% YoY) provides positive revenue momentum for the stock.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Sustained quarterly revenue levels above ₹80 crore
• Execution on power cost-saving initiatives
• Operating margin stability in sterile liquid formulations

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian sterile parenterals and pharmaceutical manufacturing sector is benefiting from stable domestic healthcare requirements and steady expansion in export markets for generic formulations.

Key Risks to Watch

• Raw material price volatility for active pharmaceutical ingredients (APIs)
• Regulatory compliance standards applicable to sterile manufacturing plants
• Competitive pricing pressure in domestic formulation markets

Recent Developments

Amanta Healthcare previously highlighted progress on its 10.8 MW captive solar power project designed to reduce operational power costs starting FY27. Additionally, the company held its Board Meeting on November 3, 2026, to consider and approve Q2 financial results.

Closing Insight

With Q2 revenue growing ≈17.21% YoY to ₹83.1 crore, Amanta Healthcare demonstrates resilient operational momentum in its core healthcare categories.

High Performance Trading with SAHI.